Laroni A - Search Results

1

CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis.

Schiavetti I, Barcellini L, Lapucci C, Tazza F, Cellerino M, Capello E, Franciotta D, Inglese M, Sormani MP, Uccelli A, Laroni A. Schiavetti I, et al. Among authors: laroni a. Mult Scler Relat Disord. 2023 Feb;70:104494. doi: 10.1016/j.msard.2022.104494. Epub 2022 Dec 30. Mult Scler Relat Disord. 2023. PMID: 36603292 Free PMC article.

2

Association of melanoma and natalizumab therapy in the Italian MS population: a second case report.

Laroni A, Bedognetti M, Uccelli A, Capello E, Mancardi GL. Laroni A, et al. Neurol Sci. 2011 Feb;32(1):181-2. doi: 10.1007/s10072-010-0427-x. Epub 2010 Nov 5. Neurol Sci. 2011. PMID: 21052756

3

Neuroprotective features of mesenchymal stem cells.

Uccelli A, Benvenuto F, Laroni A, Giunti D. Uccelli A, et al. Among authors: laroni a. Best Pract Res Clin Haematol. 2011 Mar;24(1):59-64. doi: 10.1016/j.beha.2011.01.004. Epub 2011 Feb 25. Best Pract Res Clin Haematol. 2011. PMID: 21396593 Review.

4

Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases.

Uccelli A, Laroni A, Freedman MS. Uccelli A, et al. Among authors: laroni a. Lancet Neurol. 2011 Jul;10(7):649-56. doi: 10.1016/S1474-4422(11)70121-1. Lancet Neurol. 2011. PMID: 21683930 Review.

5

Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification.

Laroni A, Giacomazzi CG, Grimaldi L, Gallo P, Sormani MP, Bertolotto A, McDermott JL, Gandoglia I, Martini I, Vitello G, Rinaldi F, Barzon L, Militello V, Pizzorno M, Bandini F, Capello E, Palù G, Uccelli A, Mancardi GL, Varnier OE. Laroni A, et al. J Neuroimmune Pharmacol. 2012 Sep;7(3):665-72. doi: 10.1007/s11481-012-9366-z. Epub 2012 May 16. J Neuroimmune Pharmacol. 2012. PMID: 22585413

6

Mesenchymal stem cells as treatment for MS - progress to date.

Uccelli A, Laroni A, Freedman MS. Uccelli A, et al. Among authors: laroni a. Mult Scler. 2013 Apr;19(5):515-9. doi: 10.1177/1352458512464686. Epub 2012 Nov 1. Mult Scler. 2013. PMID: 23124791 Review.

7

Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption.

Laroni A, Brogi D, Milesi V, Abate L, Uccelli A, Mancardi G. Laroni A, et al. Mult Scler. 2013 Aug;19(9):1236-7. doi: 10.1177/1352458512468498. Epub 2012 Nov 26. Mult Scler. 2013. PMID: 23184503 No abstract available.

8

Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system.

Laroni A, Novi G, Kerlero de Rosbo N, Uccelli A. Laroni A, et al. J Neuroimmune Pharmacol. 2013 Dec;8(5):1062-76. doi: 10.1007/s11481-013-9456-6. Epub 2013 Apr 12. J Neuroimmune Pharmacol. 2013. PMID: 23579931 Review.

9

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial.

Laroni A, Brogi D, Morra VB, Guidi L, Pozzilli C, Comi G, Lugaresi A, Turrini R, Raimondi D, Uccelli A, Mancardi GL; EAP Investigators. Laroni A, et al. BMC Neurol. 2014 Apr 1;14:65. doi: 10.1186/1471-2377-14-65. BMC Neurol. 2014. PMID: 24690227 Free PMC article. Clinical Trial.

10

Clinical baseline factors predict response to natalizumab: their usefulness in patient selection.

Laroni A, Gandoglia I, Solaro C, Ribizzi G, Tassinari T, Pizzorno M, Parodi S, Baldassarre G, Rilla MT, Venturi S, Capello E, Sormani MP, Uccelli A, Mancardi GL. Laroni A, et al. BMC Neurol. 2014 May 12;14:103. doi: 10.1186/1471-2377-14-103. BMC Neurol. 2014. PMID: 24885703 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

85 results

Search Page